🧠 Watchlist Winners: Copy Legendary Investors' Portfolios in One ClickCOPY FOR FREE

Omeros Corporation (OMER)

NASDAQ
Currency in USD
Disclaimer
3.940
+0.200(+5.35%)
Closed
After Hours
3.900-0.040(-1.015%)
OMER Scorecard
Full Analysis
Operates with a significant debt burden
Fair Value
Day's Range
3.7403.960
52 wk Range
0.9205.680
Prev. Close
3.74
Open
3.74
Day's Range
3.74-3.96
52 wk Range
0.92-5.68
Volume
261,991
Average Volume (3m)
341,837
1-Year Change
26.69%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
OMER Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Management has been aggressively buying back shares
Show more

Omeros Corporation Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Employees
198

Compare OMER to Peers and Sector

Metrics to compare
OMER
Peers
Sector
Relationship
P/E Ratio
−1.1x−4.9x−0.6x
PEG Ratio
0.000.000.00
Price/Book
−1.8x1.3x2.6x
Price / LTM Sales
-7.3x3.1x
Upside (Analyst Target)
229.9%122.1%55.8%
Fair Value Upside
Unlock13.6%7.3%Unlock

FAQ

What Is the Omeros (OMER) Stock Price Today?

The Omeros stock price today is 3.94.

What Stock Exchange Does Omeros Trade On?

Omeros is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Omeros?

The stock symbol for Omeros is "OMER."

What Is the Omeros Market Cap?

As of today, Omeros market cap is 228.31M.

What is Omeros Earnings Per Share?

The Omeros EPS is -2.31.

What Is the Next Omeros Earnings Date?

Omeros will release its next earnings report on 05 Nov 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.